NeoGenomics (NEO) Debuts PanTracer Family of Genomic Profiling Tests
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
May 28, 2025 7:10 AM EDTThe company expands precision oncology portfolio with new Paletrra spatial proteomics platform
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NeoGenomics or the Company) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracer Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30June 3, 2025. The company will also unveil Paletrra, its new AI-driven spatial proteomics platform designed to provide clear, actionable insights from tissue samples.
"The... More
